新天药业(002873) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥219,145,829.65, a decrease of 12.26% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was ¥30,660,310.74, down 25.91% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,752,176.95, a significant decline of 68.77% compared to the previous year[3]. - The net profit for the third quarter of 2024 is CNY 60,999,761.23, a decrease of 30.5% compared to CNY 87,711,668.99 in the same period last year[13]. - Total revenue for the period is CNY 660,845,257.81, down 15% from CNY 775,665,238.78 year-on-year[12]. - The company's operating profit is CNY 70,014,131.46, a decline of 32.7% from CNY 104,006,992.46 in the previous year[13]. - Earnings per share (EPS) for the period is CNY 0.2645, compared to CNY 0.3782 in the same quarter last year, reflecting a decrease of 30.2%[14]. - The investment income for the period is CNY 3,832,613.72, down 28.4% from CNY 5,354,623.20 year-on-year[12]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥1,963,490,164.97, reflecting a 2.70% increase from the end of the previous year[3]. - The total liabilities of the company amounted to CNY 916,832,310.66, compared to CNY 798,467,640.63 at the beginning of the period, indicating a rise of about 14.8%[10]. - The company's short-term borrowings rose to CNY 452,000,000.00 from CNY 366,929,222.23, reflecting an increase of approximately 23.1%[10]. - The total non-current assets reached CNY 1,301,305,276.40, up from CNY 1,275,370,863.49, showing a growth of about 2.0%[10]. - The company's equity attributable to shareholders decreased by 5.99% to ¥1,046,657,854.31 compared to the end of the previous year[3]. - The total equity attributable to shareholders of the parent company is CNY 1,046,657,854.31, down 6% from CNY 1,113,331,133.10[11]. Cash Flow - The company reported a net cash flow from operating activities of ¥54,698,235.80, which increased by 51.29% year-on-year[6]. - Cash flow from operating activities is CNY 54,698,235.80, an increase of 51.3% from CNY 36,153,971.42 in the previous year[15]. - The company reported a net cash inflow from operating activities of CNY 630,523,324.47, compared to CNY 794,177,575.88 in the previous year, indicating a decrease of 20.6%[15]. - The cash flow from investing activities improved by 38.26%, with a net outflow of ¥44,917,770.24[6]. - The net cash flow from investing activities was -44,917,770.24 CNY, compared to -72,748,316.97 CNY in the previous year, indicating an improvement[16]. - Cash inflow from financing activities totaled 509,000,000.00 CNY, up from 438,000,000.00 CNY year-over-year[16]. - Cash outflow for debt repayment increased to 364,000,000.00 CNY from 262,000,000.00 CNY, reflecting higher debt servicing costs[16]. - The net cash flow from financing activities was -11,301,145.05 CNY, a significant decline from a positive 138,871,143.28 CNY in the previous year[16]. - The ending balance of cash and cash equivalents decreased to 136,716,254.72 CNY from 202,944,468.08 CNY year-over-year[16]. - The company reported a net decrease in cash and cash equivalents of -1,520,679.49 CNY, contrasting with an increase of 102,276,921.10 CNY in the same quarter last year[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,510[7]. - The company's cash and cash equivalents decreased to CNY 136,716,254.72 from CNY 138,236,934.21, representing a decline of about 1.1%[9]. - Accounts receivable increased significantly to CNY 321,168,000.15, up from CNY 226,448,761.16, marking an increase of approximately 41.8%[9]. - The company's other current liabilities decreased to CNY 70,716.07 from CNY 130,133.45, reflecting a decline of about 45.4%[10]. - The company's equity decreased slightly from CNY 231,491,231.00 to CNY 229,450,267.00, a reduction of approximately 0.9%[10]. Research and Development - Research and development expenses increased by 30.54% to ¥29,913,962.65, indicating a focus on innovation[6]. - The company reported development expenditures of CNY 96,964,557.76, an increase from CNY 81,522,028.71, representing a growth of approximately 19.0%[10]. Audit Information - The company has not undergone an audit for the third quarter report[17].